改良多西紫杉醇、顺铂、5-氟尿嘧啶诱导化疗在局部晚期下咽鳞癌保喉中的应用。
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
机构信息
Department of Radiation Oncology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
出版信息
Head Neck. 2022 Sep;44(9):2018-2029. doi: 10.1002/hed.27119.
BACKGROUND
Previous studies have investigated the value of induction chemotherapy (IC) in organ preservation strategies for head and neck cancers. This study evaluated the effectiveness of sequential IC with radiotherapy as a laryngeal preservation strategy for locally advanced hypopharyngeal carcinoma (LAHSCC).
METHODS
One hundred and forty-two consecutive patients with LAHSCC were retrospectively analyzed who received three IC regimens from 2015 to 2019.
RESULTS
In the TP (docetaxel plus cisplatin), TPF (TP plus 5-fluorouracil), and TPX (TP plus capecitabine) IC groups, there were 51, 29, and 62 patients, respectively. The primary tumor objective response rates were 51%, 55.2%, and 71%, and the 3-year survival rates with preserved larynx were 36.6%, 31.8%, and 51.2%, respectively (p = 0.03). There was no difference in overall survival and the adverse events were tolerable.
CONCLUSIONS
The TPX regimen displayed good efficacy and safety, indicating its potential as a therapeutic IC regimen for LAHSCC.
背景
先前的研究已经探讨了诱导化疗（IC）在头颈部癌症器官保留策略中的价值。本研究评估了顺铂联合多西他赛序贯放化疗作为局部晚期下咽癌（LAHSCC）喉保留策略的有效性。
方法
回顾性分析了 2015 年至 2019 年间接受三种 IC 方案治疗的 142 例连续 LAHSCC 患者。
结果
在 TP（多西他赛联合顺铂）、TPF（TP 联合氟尿嘧啶）和 TPX（TP 联合卡培他滨）IC 组中，分别有 51、29 和 62 例患者。原发肿瘤客观缓解率分别为 51%、55.2%和 71%，保喉 3 年生存率分别为 36.6%、31.8%和 51.2%（p=0.03）。总生存率无差异，不良反应可耐受。
结论
TPX 方案显示出良好的疗效和安全性，表明其作为 LAHSCC 治疗性 IC 方案的潜力。
Zotero 插件